Prospective epidemiologic analysis of triazole-resistant nosocomial Candia glabrata isolated from patients at a comprehensive cancer center

International Journal of Infectious Diseases

Volumn 6, Issue 3, 2002, Pages 198-201

  Safdar, Amar ^a,d   Armstrong, Donald ^b   Cross, Emily W ^c   Perlin, David S ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d Div of Infect Dis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; TRIAZOLE DERIVATIVE; ANTIFUNGAL AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANCER CENTER; CANDIDA GLABRATA; CANDIDIASIS; CLINICAL ARTICLE; EPIDEMIOLOGICAL DATA; FEMALE; FUNGUS ISOLATION; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PATHOGENESIS; RANDOM AMPLIFIED POLYMORPHIC DNA; CLASSIFICATION; CROSS INFECTION; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; NEOPLASM; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE; TRIAZOLES;

EID: 0036734956     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(02)90111-6     Document Type: Article

References (21)

1. Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin 2001; 17:531-570.
2. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-1079.
3. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100: 617-623.
4. Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effects of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 2001; 28:873-878.
5. Wey SB, Mori M, Pfaller MA, et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-645.
6. Gumbo T, Isada CM, Hall G, et al. Candida glabrata fungemia-clinical features of 139 patients. Medicine 1999; 78:220-227.
7. Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999;12:80-96.
8. Safdar A, Chaturvedi V, Cross EW, et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 2001; 45:2129-2133.
9. Taylor JW, Geiser DM, Burt A, Koufopanou V. The evolutionary biology and population genetics underlying fungal strain typing. Clin Microbiol Rev 1999; 12:126-146.
10. Safdar A, Armstrong D. Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies. Bone Marrow Transplant 2002 (in press).
11. Sanford GR, Merz WG, Wingard JR, et al. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 1980; 142:503-509.
12. Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989; 64:2030-2034.
13. Pujol C, Joly S, Lockhart SR, et al. Parity among the randomly amplified polymorphic DNA method, multilocus enzyme electrophoresis, and southern blot hybridization with the moderately repetitive DNA probe Ca3 for fingerprinting Candida albicans. J Clin Microbiol 1997; 35:2348-2358.
14. Marco F, Lockhart SR, Pfaller MA, et al. Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol 1999; 37:2817-2828.
15. Lischewski A, Harmsen D, Wilms K, et al. Molecular epidemiology of Candida albicans isolated from AIDS and cancer patients using a novel standardized CARE-2 DNA fingerprinting technique. Mycosis 1999; 42:371-383.
16. Schwab U, Chernomas F, Larcom L, et al. Molecular typing and fluconazole susceptibility of urinary Candida glabrata isolates from hospitalized patients. Diagn Microbiol Infect Dis 1997; 29:11-17.
17. Vazquez JA, Dembry LM, Sanchez V, et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 1998; 36:421-426.
18. Fowler SL, Rhoton B, Springer SC, Messer SA, Hollis RJ, Pfaller MA. Evidence for person-to-person transmission of Candida lasitaniae in a neonatal intensive-care unit. Infect Control Hosp Epidemiol 1998; 19:343-345.
19. Reef SE, Lasker BA, Butcher DS, et al. Nonperinatal nosocomial transmission of Candida albicans in a neonatal intensive care unit: prospective study. J Clin Microbiol 1998; 36:1255-1259.
20. Redding SW, Pfaller MA, Messer SA, et al. Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection. J Clin Microbiol 1997; 35:1761-1765.
21. Lockhart SR, Reed BD, Pierson CL, Soll DR. Most frequent scenario for recurrent Candida vaginitis is strain maintenance with 'substrain shuffling': demonstrated by sequential DNA fingerprinting with probe Ca3, C1, and CARE2. J Clin Microbiol 1996; 34:767-777.